Blood cytokines as potential predictors of therapy effectiveness in patients with moderate to severe psoriasis treated with the IL-12/IL-23 inhibitor ustekinumab
Background. Despite the proven efficacy and safety of biologics in the treatment of psoriasis (Ps), a number of patients experience heterogeneity in response to therapy in both the short-term and long-term perspectives. Aims. To identify correlations between the blood cytokine levels, clinical se...
Saved in:
| Main Authors: | Arfenya E. Karamova, Anastasiia A. Vorontsova, Alexandr А. Nikonorov, Evgenia R. Nikonorova, Аlexey A. Kubanov |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
State Scientific Center of Dermatovenereology and Cosmetology
2025-03-01
|
| Series: | Vestnik Dermatologii i Venerologii |
| Subjects: | |
| Online Access: | https://vestnikdv.ru/jour/article/viewFile/16814/pdf_1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A case of ustekinumab-induced pustular psoriasis was treated with IL-17A inhibitor
by: LIN Junjie, et al.
Published: (2024-11-01) -
Ustekinumab Biosimilars
by: Elena Carmona-Rocha, et al.
Published: (2024-11-01) -
IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS
by: E. L. Nasonov, et al.
Published: (2019-09-01) -
Genetic Variants of the IL‐23/IL‐17 Axis and Its Association With Periodontal Disease: A Systematic Review
by: Ruth Rodríguez‐Montaño, et al.
Published: (2025-02-01) -
Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic Patient
by: Haitham M. Saad, et al.
Published: (2024-12-01)